Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
Arthritis & Rheumatology (Hoboken, N.J.)|February 26, 2025
Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart TherapySara Alehashemi, Bjoern Buehring, Adriana A de Jesus, et al.
Science Translational Medicine|May 10, 2023
Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PDMichiyo Iba, Changyoun Kim, Somin Kwon, et al.
Anti-Cancer Drugs|February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lungSanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
International Journal of Radiation Oncology, Biology, Physics|August 1, 1996
Management of thyroid carcinoma with radioactive 131IS B Paryani, R J Chobe, W Scott, et al.
Pigment Cell & Melanoma Research|July 28, 2016
Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanomaBih-Rong Wei, Helen T Michael, Charles H C Halsey, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate CancerRussell Z Szmulewitz, Cody J Peer, Abiola Ibraheem, et al.
Cancer Biology & Therapy|November 12, 2019
Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brainJonathan D Strope, Cody J Peer, Tristan M Sissung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancerMichael S Gordon, Francisco Robert, Daniela Matei, et al.
Pageof 16